In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...
You're currently following this author! Want to unfollow? Unsubscribe via the link in your email. Follow Erin McDowell Every time Erin publishes a story, you’ll get an alert straight to your inbox!
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback